Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Regeneron and Bayer Start Phase III Trial of Macular Edema Drug in China

publication date: Feb 19, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Regeneron Pharmaceuticals and Bayer HealthCare have started a new Phase III trial to test Eylea® (aflibercept) Injection as a treatment for Diabetic Macular Edema (DME). The trial will be conducted in China, Russia and other Asian countries. In its global Phase II DME program, Eylea showed promising results. More details....

Stock Symbols: (NSDQ: REGN) (Xetra: BAY)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors